VivoSeq
Ophthalmology

Thyroid Eye Disease

35

Pipeline Programs↗

32

Active Trials↗

21

Companies Involved↗

Thyroid Eye Disease is a moderately active landscape with 35 programs across 21 companies. The most active players are Zenas BioPharma (USA), LLC, Changchun GeneScience Pharmaceutical Co., Ltd., Lundbeck. 6 therapies are approved with 14 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

34/100

Mech. Concentration

22/100

Completion Rate

72/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Z

Zenas BioPharma (USA), LLC

1 program

Phase 1Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.

1 program

Phase 1Lundbeck logo

Lundbeck

1 program

Phase 1N

Nanjing Chia-tai Tianqing Pharmaceutical

1 program

Phase 2L

Lassen Therapeutics 1 PTY LTD

1 program

Phase 2P

Prism Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical2

Atorvastatin, Lipitor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Triamcinolone Acetonide

Bausch Health Americas, Inc.

Phase 13

Gensci098

Changchun GeneScience Pharmaceutical Co., Ltd.

Kamuvudine-9

Michelle Abou-Jaoude

Lu AF95245

Lundbeck

Phase 210

Artificial Tears

University Hospital of Patras

Celecoxib

Philadelphia Eye Associates

Sirolimus

Prism Pharmaceuticals

NTB003

Nanjing Chia-tai Tianqing Pharmaceutical

Otelixizumab

GSK

Phase 314

Teprotumumab

Horizon Therapeutics Ireland DAC

Secukinumab

Novartis

Tocilizumab

Roche

MHB018A

Minghui Pharmaceutical (Hangzhou) Ltd

Satralizumab

Roche

Approved6

Methylprednisolone

Pfizer

Bimatoprost

AbbVie

Timolol

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

TEPEZZA

Amgen

Teprotumumab N01

Innovent Biologics (Suzhou) Co. Ltd.

Analysis

Modality Breakdown

82%

Small molecule

37 of 45 classified programs — the dominant modality here.

18%ALL OTHERSMonoclonal antibody818%

Small molecule leads; the ring shows all 45 classified programs, each share of the total. Modality classified for 98% of 47 pipeline programs.

Analysis

Trial Status

65

clinical trials

Completed21 · 32%
Recruiting13 · 20%
Active, not recruiting12 · 18%
Not yet recruiting7 · 11%
Withdrawn4 · 6%
Terminated4 · 6%
Other4 · 6%

Clinical Trials

Trial Activity

65 trials

MHB018A Treatment in Patients With Active Thyroid Eye Disease
Recruiting·MMinghui Pharmaceutical (Hangzhou) Ltd·Phase 3·NCT06989918·108 enrolled
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
Recruiting·Changchun GeneScience Pharmaceutical Co., Ltd. logoChangchun GeneScience Pharmaceutical Co., Ltd.·Phase 1·NCT06569758·76 enrolled
Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)
Recruiting·—·Phase 1·NCT06467435·13 enrolled
Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease
Recruiting·HHaukeland University Hospital·Phase 2·NCT04936854·60 enrolled
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Recruiting·WWalter Reed National Military Medical Center·N/A·NCT06275373·100 enrolled
A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease
Recruiting·Innovent Biologics (Suzhou) Co. Ltd. logoInnovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT07113262·111 enrolled
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
Recruiting·TTourmaline Bio, Inc.·Phase 2·NCT06088979·81 enrolled
A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
Recruiting·ZZai Lab (Shanghai) Co., Ltd.·Phase 3·NCT07211776·99 enrolled
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Recruiting·SSling Therapeutics, Inc.·Phase 2/3·NCT06112340·75 enrolled
Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)
Recruiting·MMedical University of Warsaw·N/A·NCT06367517·30 enrolled
A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye Disease
Recruiting·Amgen logoAmgen·Preclinical·NCT06401044·88 enrolled
An Open-label, Rollover Study for Participants With Thyroid Eye Disease Previously Enrolled in Amgen-sponsored AMG 732 Studies and Are Primary Proptosis Non-responders or Who Relapsed During the Safety Follow-up
Recruiting·Amgen logoAmgen·Phase 2·NCT07438405·30 enrolled
TED-PROTECT: Teprotumumab in Inactive TED
Recruiting·Amgen logoAmgen·Phase 3·NCT05800004·250 enrolled
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Active, not recruiting·SSling Therapeutics, Inc.·Phase 2/3·NCT05276063·90 enrolled
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
Active, not recruiting·VViridian Therapeutics, Inc.·Phase 3·NCT06625398·195 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)